Eli Lilly and Company는 미국, 유럽, 중국, 일본 및 기타 국제 시장에서 인체용 의약품을 발굴, 개발, 제조 및 판매합니다. 이 회사는 Basaglar, Humalog, Humulin 등 당뇨병 치료제와 Jardiance, Mounjaro, Trulicity 등 제2형 당뇨병 치료제, Zepbound 등 비만 치료제를 포함한 심혈관 및 대사 건강 제품을 제공합니다.
또한 Eli Lilly and Company는 Cyramza, Erbitux, Inluriyo, Jaypirca, Retevmo, TYVYT, Verzenio 등 다양한 암 치료제를 제공하며, Ebglyss, Olumiant, Omvoh, Taltz 등 면역학 제품도 판매합니다. 이 외에도 편두통 예방 및 군발성 두통 치료제 Emgality와 증상성 알츠하이머병 치료제 Kisubla를 제공합니다.
영어 원문 보기
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
